|Bid||16.74 x 900|
|Ask||18.86 x 800|
|Day's Range||15.56 - 16.84|
|52 Week Range||7.09 - 31.43|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.00|
Nuvalent, Inc. is a clinical stage biopharmaceutical company that develops therapies for patients with cancer. In this daily bar chart of NUVL, below, we can see that prices made a low in May. January and March could be a complex left shoulder. The On-Balance-Volume (OBV) line shows a longer-term rise followed by sideways movement the past two months.
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose escalation data from its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors during an oral plenary session at the 34th EORTC-NCI-AACR (ENA) Symposium taking place October 26-28, 20
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference on Thursday, September 8, 2022, at 2:35 p.m. ET in Boston.